How Will Control Bionics’ $3.8M Raise and Tobii Deal Accelerate Growth?
Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.
- Raised over $3.8 million in capital to support growth initiatives
- Entered distribution partnership with Tobii for NeuroNode in the US
- Integrated with Apple’s Brain Computer Interface protocol
- Completed acquisition of NeuroBounce to expand sports performance offerings
- Scaled manufacturing and expanded NeuroStrip adoption amid NDIS delays
Strategic Capital Raise and Partnerships
Control Bionics Limited has marked the December 2025 quarter with a significant capital raise of over $3.8 million before costs, providing a robust financial foundation to accelerate its commercial and manufacturing ambitions. This injection of funds comes at a pivotal time as the company advances its NeuroNode distribution strategy, highlighted by a new partnership with Tobii, the world’s leading provider of Augmentative and Assistive Communication (AAC) solutions. This alliance positions Control Bionics to broaden its reach in the US market through established distribution channels.
Innovation at the Forefront, Apple BCI Integration
In a notable technological milestone, Control Bionics became one of the first organisations globally to integrate with Apple’s Brain Computer Interface (BCI) protocol. This integration not only underscores the company’s leadership in non-invasive neurotechnology but also opens doors to leveraging mainstream consumer platforms, potentially enhancing accessibility and user experience for individuals relying on assistive communication devices.
Expanding Product Portfolio and Market Footprint
The company completed the acquisition of Neuro Elite Athletics, known as NeuroBounce, at the end of 2025. This move establishes a dedicated platform for its Sports Performance program, targeting elite sports, rehabilitation, and broader performance markets primarily in the US but with international ambitions. Concurrently, the rollout of the NeuroStrip device continues to gain traction, with multiple organisations across the US and Australia, including prestigious institutions like the Australian Institute of Sport and The Mayo Clinic, actively using the technology. To meet growing demand, Control Bionics has commenced scaled manufacturing of NeuroStrip devices and consumables.
Revenue Challenges Amid Regulatory Delays
Despite these advances, revenue for the quarter remained flat at $1.4 million compared to the previous year, primarily due to significant delays in approvals from Australia’s National Disability Insurance Scheme (NDIS). These delays are affecting the broader assistive technology sector, creating a bottleneck for customer uptake. Control Bionics is actively working with customers and stakeholders to navigate these challenges, maintaining confidence in strong underlying demand.
Looking Ahead, Strategic Priorities for 2026
Looking forward, Control Bionics has outlined five strategic priorities for 2026, achieving profitability in core markets including the US, Australia, and Japan; scaling the NeuroNode business through expanded distribution; driving adoption of NeuroStrip in sports science and rehabilitation; accelerating growth via partnerships and acquisitions, including opportunities from the Apple BCI integration; and building a high-performance organisation to support sustainable growth. The company ended the quarter with a healthy cash balance of $3.1 million, positioning it well to execute on these objectives.
Bottom Line?
Control Bionics’ recent capital raise and strategic partnerships set the stage for growth, but regulatory hurdles and execution will be key to watch.
Questions in the middle?
- How quickly will the NDIS approval delays resolve, and what impact will this have on revenue?
- What commercial opportunities will arise from the Apple BCI integration in the near term?
- How will the NeuroBounce acquisition translate into measurable growth in the sports performance market?
